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Standardization of flow cytometric minimal residual
disease assessment in international clinical trials. A
feasibility study from the European Myeloma
Network
For many decades, international collaborative efforts
have driven therapeutic advances in multiple myeloma
(MM). The establishment of uniform response criteria by
the International Myeloma Working Group (IMWG) has
been pivotal for this progress, as adherence to strict defi-
nitions ensures data comparability between trials. An
essential prerequisite for the use of uniform criteria is the
application of standardized methods. Of particular inter-
est herein is the assessment of minimal residual disease
(MRD) by multiparametric flow cytometry (MFC). This
has been incorporated into the IMWG response criteria
since 2011 to enable better risk stratification of a growing
number of patients reaching a complete remission and
has the promise to be used both as a surrogate marker for
overall and progression-free survival and to inform treat-
ment decisions.1,2 However, in contrast to most routine
diagnostic tests for response assessment in MM, this
assay has until recently suffered from large interlaborato-
ry variations in terms of sample processing and data
acquisition, resulting in highly heterogeneous sensitivi-
ties.3 To enable uniform and sensitive MFC MRD assess-
ment between laboratories, EuroFlow has developed
standardized operating procedures.4-6 Their next-genera-
tion flow method has been incorporated as the gold stan-
dard for MFC MRD measurements in the latest IMWG
response criteria, which is expected to greatly improve
data validity and comparability.7
Even though the establishment of standardized proto-
cols has been an important step towards achieving uni-
form MFC MRD assessment in MM, the usefulness of
these protocols depends heavily on their successful
implementation in a wide range of laboratories. This is of
particular relevance for international clinical trials that
depend on a collaborative effort of multiple reference lab-
oratories for timely MRD assessment, irrespective of geo-
graphical location of sampling. Nevertheless, it remains
largely unknown whether fully standardized multi-labo-
ratory MM MFC MRD assessment can be achieved in
such a setting.8 To investigate this, a novel quality assur-
ance (QA) program was established in 2016 within the
framework of the European Myeloma Network (EMN):
the EMN MRD QA program. This program aims to assess
the validity and comparability of MFC MRD measure-
ments within and between EMN trials by distributing
fresh MM bone marrow and peripheral blood samples
and complements existing QA programs led by EuroFlow
using peripheral blood samples from healthy donors9 or
raw data files from MM MFC MRD measurements. Data
obtained within the EMN MRD QA program show that
it is feasible to fully standardize MFC MRD assessment
between laboratories, resulting in a high concordance
over the entire range of detectable MRD levels.
Participation in QA programs is essential to ensure com-
plete interlaboratory standardization without compro-
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Figure 1. Sample characteristics and logistics for quality assurance rounds 1-4 of the European Myeloma Network minimal residual disease quality assurance
program. A total of 20 fresh samples from patients with multiple myeloma (MM) were used in quality assurance (QA) rounds 1-4, resulting in the performance
of 67 multiparameter flow cytometry (MFC) minimal residual disease (MRD) assessments in four participating laboratories in Europe. (A) In total, 17 bone mar-
row and three peripheral blood samples were collected from MM patients with variable disease burden, with six patients receiving daratumumab treatment at
the time of sampling. Sample volumes ranged from 2-6 mL, whereas sample white blood cell counts ranged from <5 x 109/L to >25 x 109/L. Response status
was determined according to the International Myeloma Working Group (IMWG) 2016 criteria.7 (B) Between March 15, 2016 and December 17, 2019, MM sam-
ples were collected and distributed from hospitals in Rotterdam, the Netherlands and Turin, Italy. In QA rounds 1-2, second-generation flow protocols (EuroFlow)
were used by all laboratories, whereas next-generation flow protocols (EuroFlow) were used in QA rounds 3-4. All laboratories participated in the full European
Myeloma Network (EMN) MRD QA program, except for laboratory 1. In 2018 and 2019, this laboratory did not serve as a reference laboratory for any EMN trials
requiring the use of next-generation flow protocols and therefore decided to not join QA rounds 3-4. In general, laboratories were able to process 86-100% of
received samples within the IMWG recommended timeframe of 24-48 hours after sampling. CR: complete response; ID: identifier; NDMM: newly diagnosed mul-
tiple myeloma; PD: progressive disease; PR: partial response; QA: quality assurance; sCR: stringent complete response; TBSSA: time between sampling and sam-
ple arrival; TBSSP: time between sampling and sample processing; VGPR: very good partial response; WBC: white blood cell. 
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Figure 2. Concordance of minimal residual disease  levels, monoclonal plasma cell immunophenotype, and polyclonal plasma cell levels between European
Myeloma Network multiparameter flow cytometry laboratories. Minimal residual disease (MRD) levels were highly concordant between laboratories, irrespec-
tive of disease burden, disease stage, treatment status, sample type and quality assurance (QA) round. (A) A total of 10/20 (50%) samples were MRD-positive,
which could be confirmed by all laboratories in 9/10 (90%) cases, using a cutoff of ≥20 monoclonal plasma cells (mPC) for MRD positivity. MRD-negative results
were concordant between laboratories in 10/10 (100%) cases. In MRD-negative assays, a limit of detection <0.001% was reached in 11/16 (69%) samples in
QA rounds 1-2, versus 14/18 (78%) of samples in QA rounds 3-4. In contrast, a limit of quantification <0.001% was reached in 4/16 (25%) of MRD-negative
assays in QA rounds 1-2, versus 9/18 (50%) of MRD negative assays in QA rounds 3-4. MRD-positive samples showed a high degree of concordance between
laboratories at every level of (residual) disease, ranging from 0.001-0.01% to 1-10%. (B) Qualitative expression of essential markers for mPC gating (i.e., CD38,
CD138, CD45, CD19, CD56, CyIgK, CyIgL) showed a high degree of concordance between laboratories, whereas other informative markers (i.e., CD27, CD117,
CD81) showed greater variability, indicating that strict uniformization of protocols is essential to ensure reproducibility of immunophenotype data. (C) The level
of polyclonal plasma cells (pPC) is commonly used as a surrogate marker for bone marrow sample quality and generally showed a good concordance between
laboratories. Nevertheless, the concordance of pPC levels was inferior to that of mPC levels, suggesting that pPC levels are more susceptible than mPC levels
to interlaboratory variations in sample processing and data analysis strategies. ID: identifier; IP: immunophenotype; LOD: limit of detection = 20/total number




mising data quality, as minor protocol deviations were
commonly observed at initial implementation.
Between 2016 and 2019, MFC MRD results from 20
MM patients were compared within the EMN MRD QA
program among four EMN reference laboratories willing
to commit to EuroFlow protocols in the context of the
EMN02/HO95 MM trial: Aalborg University Hospital,
Denmark (laboratory 1), University Hospital Brno, Czech
Republic (laboratory 2), Erasmus MC Rotterdam, the
Netherlands (laboratory 3, EuroFlow member) and
University of Turin, Italy (laboratory 4).10,11 In total, four
QA rounds were organized, each comprising five differ-
ent fresh samples from MM patients with variable levels
of disease burden and variable treatment histories (Figure
1A). Samples were collected at Erasmus MC Rotterdam,
the Netherlands and Ospedale Molinette di Torino, Italy,
on random days throughout the year. This study was
approved by the Medical Ethical Committees of Erasmus
MC Rotterdam, the Netherlands and A.O.U. Città della
Salute e della Scienza di Torino, Italy. Written informed
consent was obtained from all participating patients, in
accordance with the Declaration of Helsinki.
Immediately after collection, samples were divided
equally and shipped by overnight express courier to the
participating laboratories. Samples from distributing hos-
pitals were kept at room temperature for 24 h to ensure
similar sample processing dates between laboratories.
Using standardized forms, MRD results were collected
centrally by one person, who kept these confidential
until the end of each QA round, after which results were
shared and discussed.
Timely sample processing is an essential prerequisite
for high validity of MFC MRD results, as MM cells have
a limited capacity to survive outside of the bone marrow.
Hence, the IMWG recommends processing MFC MRD
samples within 24-48 h. Considering all 67 samples from
QA rounds 1-4, our data show that two laboratories
were able to process 20/20 (100%) received samples
within this recommended timeframe. Laboratory 1
processed 6/7 (86%) and laboratory 4 18/20 (90%) sam-
ples within 48 h after sampling (Figure 1B).
Throughout QA rounds 1-4, laboratory 3 adhered
strictly to EuroFlow standardized operating procedures,
which was considered the reference for all other partici-
pating laboratories. In QA rounds 1-2, second-generation
flow protocols from EuroFlow were applied. QA round 1
was followed by a workshop to further standardize pro-
tocols and gating strategies, which resulted in the use of
significantly more comparable standardized operating
procedures between laboratories in QA round 2 (Online
Supplementary Tables S1 and S2). A minimal number of 20
monoclonal plasma cells (mPC) was required for MRD
positivity.12 Despite complete standardization of proto-
cols not being possible in laboratories 2 and 4 because of
ongoing consumable contracts and local unavailability of
certain reagents, MFC MRD results were highly concor-
dant in QA rounds 1-2 at every level of residual disease.
All participating laboratories reported the same MRD
result for 9/10 (90%) samples (Figure 2A).
The ability to uniformly quantify MRD irrespective of
daratumumab treatment status was tested in seven bone
marrow samples that were distributed in QA rounds 3-4.
Here, the EuroFlow next-generation flow pipeline was
implemented. This pipeline contains a multi-epitope anti-
body against CD38 in its staining panel, which circum-
vents epitope blocking by daratumumab.6 Of note, at this
stage all participating reference laboratories had commit-
ted to fully standardized protocols in terms of data collec-
tion, instrument setup, performance checks, sample
preparation, sample staining, data acquisition and data
analysis (Online Supplementary Tables S1 and S2), result-
ing in a second series of highly concordant MFC MRD
results and 10/10 (100%) samples with a uniformly clas-
sified MRD result (Figure 2A).
To compare interlaboratory test sensitivities in MRD-
negative samples, the formula for limit of detection
(LOD) was used: 20/number of acquired leukocytes. This
showed a median LOD of 5.4 x 10-6 in the 34 MRD-neg-
ative samples from QA rounds 1-4. Laboratory 3 reached
a LOD <0.001% in 10/10 (100%) MRD-negative assays,
whereas the other laboratories achieved a LOD <0.001%
in 50-80% of MRD-negative assays. Overall, in all except
one assay a LOD <0.01% was reached.
Recent reports indicate that the majority of newly diag-
nosed MM patients have detectable mPC in their 
peripheral blood (i.e., circulating tumor cells) when the
highly sensitive next-generation flow protocols are
used.13 Recent reports indicate that the majority of newly
diagnosed MM patients have detectable mPCs in their
peripheral blood (i.e., circulating tumor cells) when the
highly sensitive next-generation flow protocols are
used.13 As mPC infiltration is typically low in both newly
diagnosed MM peripheral blood and MRD bone marrow
samples and the collection of peripheral blood is substan-
tially less invasive than that of bone marrow, it has been
questioned whether newly diagnosed MM peripheral
blood samples could also be used for MM MRD QA pur-
poses. The feasibility of doing so was assessed in QA
round 4. Circulating tumor cells were uniformly detected
in 2/2 (100%) peripheral blood samples from newly diag-
nosed MM patients, both at highly comparable levels
between 0.001% and 0.01%. This indicates that periph-
eral blood samples from newly diagnosed MM patients
may indeed be used as an alternative to MRD bone mar-
row samples to assess interlaboratory standardization of
MM MRD protocols.
To test the interlaboratory concordance of the detected
mPC immunophenotypes, laboratories were asked to
report staining intensities as positive, dim or negative.
10/20 (50%) samples were classified as MRD-positive
and generally showed strong similarity between labora-
tories for markers that are essential for mPC gating:
CD38, CD138, CD45, CD19, CD56, CyIgK and CyIgL
(Figure 2B). The reported expression of other informative
markers (i.e., CD27, CD81 and CD117) showed more
variability. Even though this did not affect mPC quantifi-
cation, it underscores the importance of using strict defi-
nitions in terms of data analysis to ensure reproducibility
of mPC immunophenotype data.
Finally, MFC MRD assessment has the advantage over
molecular MRD techniques that it also generates infor-
mation on the cellular composition of non-MM popula-
tions, which could be used to infer the quality of bone
marrow samples. To this end, the EMN suggested in its
consensus from 2008 that the polyclonal plasma cell
(pPC) levels should always be stated in the final MRD
report.14 To test the concordance of this reference popula-
tion between laboratories, information on pPC levels was
collected from all samples in QA rounds 2-4 (Figure 2C).
As expected, peripheral blood samples had a lower medi-
an pPC level than bone marrow samples. The interlabo-
ratory concordance of reported pPC levels was generally
good, although it was inferior to that of reported MRD
levels, suggesting that pPC levels are more susceptible
than mPC levels to interlaboratory variations in sample
processing and data analysis.
In conclusion, our data indicate that full standardiza-
tion of interlaboratory MM MFC MRD assessment is fea-
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sible, resulting in highly concordant MRD data.
Moreover, QA programs using fresh material from MM
patients are a straightforward and effective way to mon-
itor and improve MFC MRD data quality within clinical
trials. This is of particular relevance for studies that
depend on reference laboratories with no or limited prior
experience with the EuroFlow protocols, as these are not
always fully adhered to from the beginning. We, there-
fore, strongly recommend the incorporation of both the
annual EuroFlow QA rounds and trial group-specific QA
rounds with fresh MM samples in future clinical trial
designs to ensure further advancement of the field in
terms of standardized MFC MRD response assessment.
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